Sarcoidosis and Cancer: The Role of the Granulomatous Reaction as a Double-Edged Sword
Authors:
- Angela Maria Di FrancescoAFAngela Maria Di Francesco
- Giuliana PasciutoGPGiuliana Pasciuto
- Elena VerrecchiaEVElena Verrecchia
- Ludovico Luca SicignanoLSLudovico Luca Sicignano
- Laura GerardinoLGLaura Gerardino
- Maria Grazia MassaroMMMaria Grazia Massaro
- Andrea UrbaniAUAndrea Urbani
- Raffaele MannaRMRaffaele Manna
Open Access
- 4 September 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5232
Abstract
Background/Objectives: The relationship between sarcoidosis and the occurrence of neoplasia deserves to be investigated, but this relation has been observed in different and heterogeneous populations, leading to conflicting data. To clarify the causal relationship between these two diseases, different risk factors (e.g., smoking), concurrent comorbidities, corticosteroid therapy, and metastasis development—as an expression of cancer aggressiveness—were investigated. Methods: In a retrospective study on 287 sarcoidosis outpatients at the Pneumological Department of the Gemelli Foundation (Rome, Italy) between 2000 and 2024, the diagnosis of cancer was recorded in 36 subjects (12.5%). Results: The reciprocal timeline of the diseases showed three different scenarios: (1) cancer preceding sarcoidosis or sarcoid-like reactions (63.8%); (2) cancer arising after sarcoidosis diagnosis (8.3%); and (3) sarcoidosis accompanying the onset of malignancy (27.8%). Only two subjects with sarcoidosis and cancer showed metastasis, and one of them was affected by lymphoma. Conclusions: These data suggest that granulomatous inflammation due to sarcoidosis may assume an ambivalent role as a “double-edged sword”, according to the M1/M2 macrophage polarization model: it represents a protective shield, preventing the formation of metastasis through the induction of immune surveillance against cancer while, on the other hand, it can be a risk factor for carcinogenesis due to the persistence of a chronic active inflammatory status. Low-dose steroid treatment was administered in only 31.6% of the cancer–sarcoidosis subjects for less than six months to control inflammation activity, with no promotive effect on carcinogenesis observed.Keywords
Funding Information
- Gemelli Policlinic Foundation IRCCS, Rare Diseases Donation (5502162)
- Research Center of Periodic Fevers of the Catholic University (5502162)
This publication has 91 references indexed in Scilit:
- Deep convolutional neural network for differentiating between sarcoidosis and lymphoma based on [18F]FDG maximum-intensity projection imagesEuropean Radiology, 2023
- Sarcoid-like reaction in cases treated by checkpoint inhibitorsMedical Oncology, 2021
- Sarcoid-like reactions: a potential pitfall in oncologic imagingEuropean Journal of Nuclear Medicine and Molecular Imaging, 2020
- Macrophage plasticity, polarization, and function in health and diseaseJournal of Cellular Physiology, 2018
- The Rho–ROCK pathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemiaThe Journal of Pathology, 2016
- Risk of Malignancy Among Patients With Sarcoidosis: A Population‐Based Cohort StudyArthritis Care & Research, 2016
- Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?Wiener Medizinische Wochenschrift, 2014
- A cohort study of cancer among sarcoidosis patientsInternational Journal of Cancer, 2009
- Autoimmune disease in individuals and close family members and susceptibility to non‐Hodgkin's lymphomaArthritis & Rheumatism, 2008
- Serum Vascular Endothelial Growth Factor as a Possible Prognostic Indicator in SarcoidosisLung, 2003